Korean biopharmaceutical companies face dismal outlook

Published: 2013-04-23 06:59:00

Updated: 2013-04-23 06:59:00

In the early 2000s, Korea was basking in the biotechnology boom thanks largely to advanced stem cell research. Strong government support led many research centers to open up bio-related facilities including cord blood banks. The biotechnology heyday didn’t last long. It was dealt a serious blow w...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK